Tumor-suppressive activity of the PARP inhibitor, Olaparib, was evaluated by using different methods of MTT assay, cell counting, and colony formation assays in the three human gastric cancer cell lines of MKN28, MKN74, and NCI-N87. The gene discussed is PARP1; the disease is gastric cancer.